Compare Manchester United PLC (MANU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Repligen Corporation Common Stock — how do they compare? Manchester United PLC trades at $20.68 (market cap $3.64B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.1× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Repligen Corporation Common Stock for 0 Days on average.
| MANU | RGEN | |
|---|---|---|
Market Cap | $3.64B | $11.14B |
Volume | 324,608 | 1,259,263 |
Sector | Media | Health |
52-Week High | $24.19 | $194.57 |
52-Week Low | $15.20 | $102.87 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $4.46B | $11.02B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.59, down 1.15% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported fiscal 2026 revenue of $678 million with improved EBITDA of $216.4 million despite net losses, while analyst sentiment remains divided with 40% buy ratings. Recent news highlights the stock trading at a significant discount to Forbes' $7.2 billion franchise valuation estimate.
Investment outlook balances franchise value upside against persistent profitability challenges. Key opportunities include Champions League return and cost controls, while risks center on sustained losses, high debt, and competitive Premier League dynamics. The stock offers speculative appeal for franchise value believers but requires profitability improvement for sustained gains.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
